A Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer's disease; Part II: open-label extension for participating patients
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Gantenerumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Marguerite RoAD
- Sponsors Chugai Pharmaceutical; Roche
- 24 Oct 2019 Planned End Date changed from 20 Nov 2020 to 22 Apr 2021.
- 24 Oct 2019 Planned primary completion date changed from 20 Nov 2020 to 22 Apr 2021.
- 11 Oct 2019 This trial has been completed in France.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History